Dermal penetration potential of perfluorooctanoic acid (PFOA) in human and mouse skin

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 75, Issue 1, 2012, Pages 50-62

  Franko, Jennifer ^a   Meade, B J ^a   Frasch, H Frederick ^a   Barbero, M ^a   Anderson, Stacey E ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; CYTOKINE; PERFLUOROOCTANOIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CORROSION; CYTOKINE PRODUCTION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; HUMAN TISSUE; IONIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ABSORPTION; SKIN PENETRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CYTOKINES; DERMIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROCARBONS; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; OCTANOIC ACIDS; SKIN ABSORPTION;

MURINAE; MUS;

EID: 81255169217     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287394.2011.615108     Document Type: Article

References (34)

1. Anderson-Mahoney, P., Kotlerman, J., Takhar, H., Gray, D., and Dahlgren, J. 2008. Selfreported health effects among community residents exposed to perfluorooctanoate. N. Solut. 18: 129-43.
2. Anderson, S. E., Butterworth, L., Jackson, L. G.,Frasch, H. F., Franko, J., and Meade, B. J. 2009. Adjuvancy and immunosuppression: Mechanisms of immunomodulation following dermal exposure to PFOA in mice. Toxicologist 108: 467.
3. Arp, H. P., Niederer, C., and Goss, K. U. 2006 Predicting the partitioning behavior of various highly fluorinated compounds. Environ. Sci. Technol. 40: 7298-304.
4. Barton, C. A., Botelho, M. A., and Kaiser, M. A. 2007 Solid vapor pressure and enthalpy of sublimation for perfluorooctanoic acid. J. Chem. Eng. Data 53: 7298-303.
5. Betts, K. S. 2007. Perfluoroalkyl acids: What is the evidence telling us? Environ. Health Perspect. 115: A250-56.
6. Burns, D. C., Ellis, D. A., Li, H., McMurdo, C. J., and Webster, E. 2008. Experimental pKa determination for perfluorooctanoic acid (PFOA) and the potential impact of pKa concentration dependence on laboratory-measured partitioning phenomena and environmental modeling. Environ. Sci. Technol. 42: 9283-88.
7. Calafat, A. M., Needham, L. L., Kuklenyik, Z., Reidy, J. A., Tully, J. S., Aguilar-Villalobos, M., and Naeher, L. P. 2006. Perfluorinated chemicals in selected residents of the American continent. Chemosphere 63: 490-96.
8. Calafat, A. M., Wong, L. Y., Kuklenyik, Z., Reidy, J. A., and Needham, L. L. 2007. Polyfluoroalkyl chemicals in the U.S. population: Data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ. Health Perspect. 115: 1596-602.
9. Corsini, E., and Galli, C. L. 1998. Cytokines and irritant contact dermatitis. Toxicol. Lett. 102- 103: 277-82.
10. DeWitt, J. C., Copeland, C. B., and Luebke, R. W. 2009b. Suppression of humoral immunity by perfluorooctanoic acid is independent of elevated serum corticosterone concentration in mice. Toxicol. Sci. 109: 106-12.
11. Dewitt, J. C., Copeland, C. B., Strynar, M. J. and Luebke, R. W. 2008. Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ. Health Perspect. 116: 644-50.
12. DeWitt, J. C., Shnyra, A., Badr, M. Z., Lovelss, S. E., Hoban, D., Frame, S. R., Cunard, R., Anderson, S. E., Meade, B. J., Peden- Adams, M. M., Luebke, R. W., and Luster, M. I. 2009a. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferatoractivated receptor alpha. Crit. Rev. Toxicol. 39: 76-94.
13. European Centre for the Validation of Alternative Methods. 2000 ESAC statement on the application of the EpiDerm human skin model for skin corrosivity testing. European Centre for the Validationof Alternative Methods. Available at: http://ecvam.jrc.ec.europa.eu/publication/ EpiDerm-statement.pdf (accessed March 14, 2011).
14. Fairley, K. J., Purdy, R., Kearns, S., Anderson, S. E., and Meade, B. J. 2007. Exposure to the immunosuppressant, perfluorooctanoic acid, enhances the murine IgE and airway hyperreactivity response to ovalbumin. Toxicol. Sci. 97: 375-83.
15. Fasano, W. J., Kennedy, G. L., Szostek, B., Farrar, D. G., Ward, R. J., Haroun, L., and Hinderliter, P. M. 2005. Penetration of ammonium perfluorooctanoate through rat and human skin in vitro. Drug Chem. Toxicol. 28: 79-90.
16. Frasch, H. F., and Barbero, A. M. 2005. Application of solid-phase microextraction to in vitro skin permeation experiments: example using diethyl phthalate. Toxicol. In Vitro 19: 253-59.
17. ICCVAM. 2002. ICCVAM Evaluation of EPISKINTM, EpiDermTM (EPI-200), and the rat skin transcutaneous electrical resistance (TER) assay: In vitro test methods for assessing the dermal corrosivity potential of chemicals. The Interagency Coordinating Committee on the Validation of Alternative Methods and the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicicological Methods. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Environmental Health Sciences, NIH publication number 02-4502. Available at: http://iccvam. niehs.nih.gov/methods/dermal/epiderm.htm (accessed March 14, 2011)
18. Kaiser, M. A., Dawson, B. J., Barton, C. A., and Botelho, M. A. 2010. Understanding potential exposure sources of perfluorinated carboxylic acids in the workplace. Ann. Occup. Hyg. 54: 915-22.
19. Kennedy, G. L., Butenhoff, J. L., Olsen, G. W., O'Connor, J.C., Seacat, A. M., Perkins, R. G., Biegel, L. B., Murphy, S. R., and Farrar, D. G. 2004. The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 34: 351-84.
20. Kudo, N., and Kawashima, Y. 2003. Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J. Toxicol. Sci. 28: 49-57.
21. Kuklenyik, Z., Needham, L. L., and Calafat, A. M. 2005. Measurement of 18 perfluorinated organic acids and amides in human serum using on-line solid-phase extraction. Anal. Chem. 77: 6085-91.
22. Liu, X., Testa, B., and Fahr, A. 2010. Lipophilicity and its relationship with passive drug permeation. Pharm. Res. 28: 962-77.
23. Moussion, C., Ortega, N., and Girard, J. P. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel 'alarmin'? PLoS One 3: e3331.
24. Olsen, G. W., Burris, J. M., Ehresman, D. J., Froehlich, J. W., Seacat, A. M., Butenhoff, J. L., and Zobel, L. R. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 115: 1298-305.
25. Ping, J., Rodgers, P. J., and Ameniya, S. 2009 High lipophilicity of perfluoroalkyl carboxylate and solfonate: Implications for their membrane permeability. J. Am. Chem. Soc. 131: 2290-96.
26. Rayne, S., and Forest, K. 2009. Perfluoroalkyl sulfonic and carboxylic acids: A critical review of physicochemical properties, levels and patterns in waters and wastewaters, and treatment methods. J. Environ. Sci. Health A Tox. Hazard. Subst. Environ. Eng. 44: 1145-99
27. Sabourin, C. L., Petrali, J. P., and Casillas, R. P. 2000. Alterations in inflammatory cytokine gene expression in sulfur mustard-exposed mouse skin. J. Biochem. Mol. Toxicol. 14: 291-302
28. Shinoda, K., Hato, M., and Hayashi, T. 1972. Physicochemical properties of aqueous solutionsof fluorinated surfactants. J. Phys. Chem. 76: 909-14.
29. Shore, P. A., Brodie, B. B., and Hogben, C. A. 1957. The gastric secretion of drugs: A pHpartition hypothesis. J. Pharmacol. Exp. Ther. 119: 361-69.
30. U.S. Environmental Protection Agency. 2006. Revised draft hazard assessment of perfluorooctanoic acid and its salts. Office of Pollution Prevention and Toxics, Risk Assessment Division. http://www.epa.gov/ sab/pdf/sab-06-006.pdf
31. Vecchia, B. E., and Bunge, A. L. 2003. Skin absorption databases and predictive equations. In Transdermal drug delivery, 2nd ed., R. H. Guy and J. Hadgraft, eds., 59-63. New York: Marcel Dekker.
32. Wittmann, M., Macdonald, A., and Renne, J. 2009. IL-18 and skin inflammation. Autoimmun. Rev. 9: 45-48.
33. Yang, Q., Abedi-Valugerdi, M., Xie, Y., Zhao, X. Y., Möller, G., Nelson, B. D., and DePierre, J. W. 2002. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2: 389-97.
34. Yang, Q., Xie, Y., Eriksson, A. M., Nelson,B. D., and DePierre, J. W. 2001. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. Biochem. Pharmacol. 62: 1133-40.